Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate
Benzinga Newsdesk 2 months ago
NewsEarningsEarnings Beats
Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per
Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per share from the same period last year. The company reported quarterly sales of $21.624 million which beat the analyst consensus estimate of $7.210 million by 199.92 percent. This is a 74.95 percent decrease over sales of $86.330 million the same period last year.